The nomination committee in
After ChemoTech built a clinical platform and strategy in recent years to take the company's technology into areas such as deep-seated tumors and immunotherapy, the company is now entering a commercialization phase in earnest.
Against this background, the nomination committee nominates
To supplement the board with a person who has global experience in product launches and commercialization of medical technology products as well as pharmaceutical products in
Nicolas has had a career within
Lars Hedbys does not wish to run for re-election as a member and is making his seat available.
Martin Jerndal is making his place available as he wishes to focus on the family business, but has indicated that he still intends to be an active and long-term owner of ChemoTech.
"It has been intense, pleasant and very interesting election committee work before the annual general meeting. Board members and shareholders have been very positive and have given constructive answers to the questions in the interview work, and these constructive publications and information gathering in the conversations have led to the nominations that the nomination committee proposed. The nominations completely reflect how you want to see ChemoTech and its continued work to strengthen and drive the commercialization of ChemoTech's products going forward," says Roland Möller, chairman of the nomination committee.
For further information:
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Certified Adviser:
E-mail:certifiedadviser@redeye.se
ChemoTech is a Swedish medical technology company based in
https://news.cision.com/chemotech/r/the-nomination-committee-proposes-changes-to-scandinavian-chemotech-s-board-to-strengthen-the-focus-,c3750902
https://mb.cision.com/Main/14967/3750902/1984235.pdf
(c) 2023 Cision. All rights reserved., source